ClinicalTrials.gg
CompletedNCT04708782TETON-1Updated Nov 20, 2026Results posted

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of Placebo and Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by United Therapeutics. Completed at 96 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
598
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
13th of 188
598 · median 61
Started
2021
with 8 others
Phase 3
37 of 236
6 open now
Registered
160th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 13th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2021, is one of 37 in phase 3, and was the 160th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

Read the detailed description

Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.

Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.

Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject gives voluntary to participate in the study.
  2. Subject is ≥40 years of age, inclusive, at the time of signing informed consent.
  3. The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung .
  4. FVC ≥45% predicted at Screening.
  5. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
  6. Women of must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of for the duration of the study, and at least 30 days after discontinuing study drug.
  7. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
  8. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or lactating.
  2. Subject has primary obstructive airway physiology: /FVC \<0.70 at Screening.
  3. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  4. The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
  5. Use of any of the following medications: azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline; cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior to Baseline.
  6. The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  7. Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
  8. Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
  9. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
  10. Use of any other drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
  11. \<6 months due to IPF or a concomitant illness.
  12. Acute pulmonary embolism within 90 days prior to Baseline.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
598 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo inhaled using an ultrasonic nebulizer QID

    Drug: Placebo · Device: Treprostinil Ultrasonic Nebulizer

  • Experimental
    Inhaled Treprostinil

    Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.

    Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer

Interventions

  • DrugPlacebo

    Placebo administered QID

  • DrugTreprostinilStudies of TreprostinilTreprostinil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Inhaled treprostinil (6 mcg/breath) administered QID

    Also known as: Tyvaso

  • DeviceTreprostinil Ultrasonic Nebulizer

    Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

06

What researchers measure

Primary outcomes

  1. Change in Absolute FVC From Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Time to Clinical Worsening

    Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

    Time frame: Baseline to Week 52

  2. Time to First Acute Exacerbation of IPF

    An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

    Time frame: Baseline to Week 52

  3. Overall Survival at Week 52

    Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).

    Time frame: Week 52

  4. Change in % Predicted FVC From Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.

    Time frame: Baseline to Week 52

  5. Change in K-BILD Questionnaire Score From Baseline to Week 52

    The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.

    Time frame: Baseline to Week 52

  6. Change in DLCO From Baseline to Week 52

    The DLCO measurement measures how well oxygen moves from the lungs to the blood.

    Time frame: Baseline to Week 52

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneInhaled TreprostinilPlacebo
Started299299
Completed218216
Not completed8183
Withdrew: Adverse event1922
Withdrew: Death814
Withdrew: Progressive disease15
Withdrew: Lung transplantation66
Withdrew: Lost to follow-up31
Withdrew: Physician decision54
Withdrew: Withdrawal by subject3831
Withdrew: Unable to attend final visit10

Outcome measures

PrimaryChange in Absolute FVC From Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

Time frame:
Baseline to Week 52
Reported as:
Median · mL
Change in Absolute FVC From Baseline to Week 52
mLInhaled TreprostinilPlacebo
Change in Absolute FVC From Baseline to Week 52-43.3 (-92.1 to -9.1)-196.2 (-227.1 to -155.6)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = <0.0001 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 130.1 · 95% CI 82.2 to 178.1Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryTime to Clinical Worsening

Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Time to Clinical Worsening
ParticipantsInhaled TreprostinilPlacebo
Time to Clinical Worsening95133
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.0036 (P-value was calculated with log-rank test stratified by baseline background therapy category.)
  • Inhaled Treprostinil vs Placebo · Regression, Cox · p = 0.0034 · Hazard ratio (hr): 0.67 · 95% CI 0.52 to 0.88
SecondaryTime to First Acute Exacerbation of IPF

An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Time to First Acute Exacerbation of IPF
ParticipantsInhaled TreprostinilPlacebo
Time to First Acute Exacerbation of IPF1019
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.0728 (P-value was calculated with log-rank test stratified by baseline background therapy category.)
  • Inhaled Treprostinil vs Placebo · Regression, Cox · p = 0.0765 · Hazard ratio (hr): 0.50 · 95% CI 0.23 to 1.08
SecondaryOverall Survival at Week 52

Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).

Time frame:
Week 52
Reported as:
Count of participants · Participants
Overall Survival at Week 52
ParticipantsInhaled TreprostinilPlacebo
Overall Survival at Week 522232
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.1248 (P-value was calculated with log-rank test stratified by baseline background therapy category.)
  • Inhaled Treprostinil vs Placebo · Regression, Cox · p = 0.1257 · Hazard ratio (hr): 0.50 · 95% CI 0.38 to 1.13
SecondaryChange in % Predicted FVC From Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.

Time frame:
Baseline to Week 52
Reported as:
Median · percentage of predicted
Change in % Predicted FVC From Baseline to Week 52
percentage of predictedInhaled TreprostinilPlacebo
Change in % Predicted FVC From Baseline to Week 52-1.4 (-2.5 to -0.3)-5.4 (-6.2 to -4.7)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = <0.0001 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 3.7 · 95% CI 2.4 to 5.0Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryChange in K-BILD Questionnaire Score From Baseline to Week 52

The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.

Time frame:
Baseline to Week 52
Reported as:
Median · scores on a scale
Change in K-BILD Questionnaire Score From Baseline to Week 52
scores on a scaleInhaled TreprostinilPlacebo
Change in K-BILD Questionnaire Score From Baseline to Week 52-1.1 (-2.1 to 0.0)-2.4 (-3.8 to -1.2)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = 0.0760 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 1.40 · 95% CI -0.15 to 2.94Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryChange in DLCO From Baseline to Week 52

The DLCO measurement measures how well oxygen moves from the lungs to the blood.

Time frame:
Baseline to Week 52
Reported as:
Median · mmol/min/kPa
Change in DLCO From Baseline to Week 52
mmol/min/kPaInhaled TreprostinilPlacebo
Change in DLCO From Baseline to Week 52-0.3 (-0.4 to -0.1)-0.3 (-0.4 to -0.2)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = 0.0945 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 0.14 · 95% CI -0.02 to 0.30Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.

Adverse events

Collected over Adverse events (AEs) were recorded throughout the course of the study from the time that each subject signed the ICF until the time screen failure was documented, or until the subject withdrew consent and discontinued from the study; or until resolution, until judged by the Investigator to no longer be clinically significant, or for at least 30 days beyond the final study visit at Week 52 study for up to an average of 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Treprostinil22/299 (7.4%)54/299 (18.1%)287/299 (96%)
Placebo34/299 (11.4%)72/299 (24.1%)280/299 (93.6%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventInhaled TreprostinilPlacebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders9/29914/299
Acute respiratory failureRespiratory, thoracic and mediastinal disorders7/29914/299
PneumoniaInfections and infestations10/2996/299
InfluenzaInfections and infestations0/2994/299
SyncopeNervous system disorders4/2991/299
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2994/299
Chest painGeneral disorders3/2991/299
PneumothoraxRespiratory, thoracic and mediastinal disorders3/2991/299
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2993/299
Cardiac failure congestiveCardiac disorders2/2992/299
Most frequent other events
Showing 10 of 29
Most frequent other events
EventInhaled TreprostinilPlacebo
CoughRespiratory, thoracic and mediastinal disorders164/29999/299
HeadacheNervous system disorders91/29948/299
DiarrheaGastrointestinal disorders49/29963/299
DyspneaRespiratory, thoracic and mediastinal disorders56/29947/299
FatigueGeneral disorders47/29945/299
DizzinessNervous system disorders44/29936/299
Throat irritationRespiratory, thoracic and mediastinal disorders42/29916/299
COVID-19Infections and infestations25/29939/299
NauseaGastrointestinal disorders33/29937/299
Upper respiratory tract infectionInfections and infestations36/29929/299

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inhaled TreprostinilPlaceboTotal
Median73.0 (52 to 91)74.0 (53 to 89)73.0 (52 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled TreprostinilPlaceboTotal
Female7165136
Male228234462
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inhaled TreprostinilPlaceboTotal
American Indian or Alaska Native213
Asian141125
Native Hawaiian or Other Pacific Islander011
Black or African American5611
White270271541
More than one race145
Unknown or Not Reported7512
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inhaled TreprostinilPlaceboTotal
Hispanic or Latino131730
Not Hispanic or Latino279276555
Unknown or Not Reported7613
Time Since IPF Diagnosis
Time Since IPF Diagnosis(years)Inhaled TreprostinilPlaceboTotal
Median2.920 (0.09 to 21.39)2.750 (0.08 to 21.03)2.830 (0.08 to 21.39)
Background Therapy at Randomization
Background Therapy at Randomization(Participants)Inhaled TreprostinilPlaceboTotal
No Background therapy6866134
Nintedanib132143275
Pirfenidone9990189
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC)(mL)Inhaled TreprostinilPlaceboTotal
Median2626.0 (1019 to 6375)2645.5 (1067 to 5065)2636.0 (1019 to 6375)
% Predicted FVC
% Predicted FVC(percentage of predicted)Inhaled TreprostinilPlaceboTotal
Median72.40 (39.0 to 128.3)72.75 (43.9 to 122.7)72.60 (39.0 to 128.3)

4 further baseline measures are reported on the registry.

08

Study locations

96 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Banner University Medical Center-Phoenix
    Phoenix, Arizona 85006, United States
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85012, United States
  • St. Joseph's Hospital and Medical Center - Norton Thoracic Institute
    Phoenix, Arizona 85013, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • UC San Diego Health
    La Jolla, California 92037, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • NewportNativeMD, Inc
    Newport Beach, California 92663, United States
  • University of California, Irvine
    Orange, California 92868, United States
  • Palmtree Clinical Research, Inc.
    Palm Springs, California 92262, United States
  • UC Davis Health Medical Center
    Sacramento, California 95817, United States
  • University of California - San Francisco
    San Francisco, California 94143, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • St. Francis Sleep Allergy & Lung Institute
    Clearwater, Florida 33765, United States
  • University of Florida Health at Shands
    Gainesville, Florida 32610, United States
  • Ascension St. Vincent's
    Jacksonville, Florida 32204, United States
  • University of Florida
    Jacksonville, Florida 32209, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Pulmonary Disease Specialists, PA d/b/a PDS Research
    Kissimmee, Florida 34741, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • Coastal Pulmonary & Critical Care PLC
    St. Petersburg, Florida 33704, United States
  • University of South Florida Health
    Tampa, Florida 33606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Piedmont Healthcare Atlanta
    Atlanta, Georgia 30309, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush University Medical Center Outpatient Pulmonary Clinic
    Chicago, Illinois 60612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Community Health Network
    Indianapolis, Indiana 46250, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Norton Pulmonary Specialists
    Louisville, Kentucky 40202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • LSU Health Sciences Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Tulane University Medical Center
    New Orleans, Louisiana 70112, United States
  • LSU Health Science Center Shreveport
    Shreveport, Louisiana 71103, United States
  • Johns Hopkins Asthma & Allergy Center
    Baltimore, Maryland 21224, United States
  • Adventist Healthcare White Oak Medical CEnter
    Silver Spring, Maryland 20904, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan Int Med Pulmonary and critical care
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Corewell Health William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • The Lung Research Center
    Chesterfield, Missouri 63017, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Creighton University Clinical Research Office
    Omaha, Nebraska 68124, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87106, United States
  • Stony Brook Advanced Specialty Care
    Commack, New York 11725, United States
  • St Joseph's Physician's Pulmonary Health
    Liverpool, New York 13088, United States
  • Northwell Health
    New Hyde Park, New York 11040, United States
  • University of Rochester Medical center
    Rochester, New York 14642, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • PulmonIx, LLC
    Greensboro, North Carolina 27403, United States
  • East Carolina University and Leo Jenkins Cancer Center
    Greenville, North Carolina 27834, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion
    Columbus, Ohio 43221, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • The Oregon Clinic, PC
    Portland, Oregon 97220, United States
  • Penn State Milton S. Hershey Medical Center/Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thoams Jefferson,Hospital University
    Philadelphia, Pennsylvania 19107, United States
  • Temple Lung Center
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Prisma Health Midlands
    Columbia, South Carolina 29203, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Statecare Pulmonary Consultants
    Knoxville, Tennessee 37919, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Univrsity of Texas Southwestern Medical Center
    Dallas, Texas 75390-8550, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • Baylor Clinic-Baylor College of Medicine
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • A & A Research Consultants, LLC
    McAllen, Texas 78503, United States
  • Metroplex Pulmonary and Sleep Center PA
    McKinney, Texas 75069, United States
  • Renovatio Clinical Consultants, LLC
    The Woodlands, Texas 77380, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • University of Utah Health
    Salt Lake City, Utah 84108, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • University of Wisconsin School of Medicine and Public health
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St.Paul's Hospital
    Vancouver, British Columbia V6Z1Y6, Canada
  • Dynamic Drug Advancement Limited
    Ajax, Ontario L1S 2J5, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite
    Québec, Quebec G1V 4G5, Canada
  • Centre d'investigation Clinique Mauricie
    Trois-Rivières, Quebec G8T 7A1, Canada
09

References and documents

Publications

  • Hwang S, Fuentes M, Lederer J, Mitkus S, Rivas-Fuentes S, Nathan SD. A plain language review of the TETON-1 and TETON-2 studies: inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2026 Nov 2:1-10. doi: 10.1080/17476348.2026.2743298. Online ahead of print. PubMed 42972641 ↗
  • Nathan SD, Smith P, Deng C, Golden J, Reynaud-Gaubert M, Farr G, Bregman B, Crossno PF, Harari S, Gupta N, Jouneau S, Adir Y, Molina-Molina M, Breytenbach N, Peterson L, Bell H, Zywot E, Rao Y, Flaherty KR, Cottin V, Behr J; TETON-1 and TETON-2 Trial Investigators. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026 Sep 23:aamag507. doi: 10.1093/ajrccm/aamag507. Online ahead of print. PubMed 42776606 ↗
  • Nathan SD, Smith P, Deng C, King CS, De Salvo M, Weigt SS, Pandya S, Bandyopadhyay D, Lasky JA, Krishna R, Hambly N, Ramaswamy M, Kebbe J, Ettinger N, Gao J, Rao Y, Breytenbach N, Peterson L, Bell H, Behr J, Cottin V, Flaherty KR; TETON-1 Trial Investigators. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026 Jul 9;395(2):115-126. doi: 10.1056/NEJMoa2501488. Epub 2026 May 18. PubMed 42149993 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Feb 2026, 57 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 57 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2021 → Apr 2021, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 14, 2021
StartActual
Apr 21, 2021was Jun 2021
Primary completionActual
Feb 2, 2026
CompletionActual
Feb 2, 2026
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Sites
2 sites added, 4 sites removed; no longer in Chile
Show 2 added (1 United States, 1 Canada)
  • Stony Brook Advanced Specialty Care · Commack, United States
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite · Québec, Canada
Show 4 removed
  • Stony Brook Advanced Specialty Care · Stony Brook, United States
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite · Québec, Canada
  • Fundacion Medica San Cristobal · Santiago, Chile
  • Centro Respiratorio Integral LTDA. (CENRESIN) · Quillota, Chile
Nov 20, 2026
Start date
Jun 1, 2021→Apr 21, 2021
Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Absolute FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
Nov 20, 2026
Documents
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42972641 ↗
Nov 20, 2026
Secondary outcomes
3 edited, 3 description edited
What changed in the outcomes
  • EditedChange in % Predicted FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • EditedChange in K-BILD Questionnaire Score fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • EditedChange in DLCO fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • DescriptionOverall Survival at Week 52: how it is measured was reworded
  • DescriptionTime to Clinical Worsening: how it is measured was reworded
  • DescriptionTime to First Acute Exacerbation of IPF: how it is measured was reworded
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42972641 ↗
    2 sites added, 4 sites removed; no longer in Chile
    Show 2 added (1 United States, 1 Canada)
    • Stony Brook Advanced Specialty Care · Commack, United States
    • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite · Québec, Canada
    Show 4 removed
    • Stony Brook Advanced Specialty Care · Stony Brook, United States
    • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite · Québec, Canada
    • Fundacion Medica San Cristobal · Santiago, Chile
    • Centro Respiratorio Integral LTDA. (CENRESIN) · Quillota, Chile
    Start date Jun 1, 2021→Apr 21, 2021
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Absolute FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    Secondary outcomes 3 edited, 3 description edited
    What changed in the outcomes
    • EditedChange in % Predicted FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • EditedChange in K-BILD Questionnaire Score fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • EditedChange in DLCO fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • DescriptionOverall Survival at Week 52: how it is measured was reworded
    • DescriptionTime to Clinical Worsening: how it is measured was reworded
    • DescriptionTime to First Acute Exacerbation of IPF: how it is measured was reworded
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04708782
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Apr 21, 2021
Primary completion
Feb 2, 2026
Completion
Feb 2, 2026
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion